Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 23

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 2
Chunk 23
---
───────────────────────────────────────────────────────────────────
  Net                                                                      168,655                 328,734  
  Net                                                   $                    1,045      $          (42,934  
  Cash,                                                                        716                 121,037  
  Cash,                                                 $                    1,761      $           78,114  

Liquidity
and Capital Resources

Operating
Activities

Net
cash used in operating activities for the six months ended March 31, 2025 was $167,609, compared to $371,658, for the same period ended
2024, a decrease of $204,049. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses
incurred by the Company during the six months ended March 31, 2025 as compared to the same period ended 2024.

Financing
Activities

Net
cash generated by financing activities for the six months ended March 31,2025 was $168,655 which consisted of proceeds from notes payables.

Liquidity
& Capital Resources Outlook

As
of December 31, 2024, the Company had cash of $ 1,761 and net working capital of ($5,716,131)

The
Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has
incurred and expects to continue incur significant research & development cost for products development.

The
accompanying financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant
operating losses and negative cash flows from operations since inception. As of March 31, 2025, the Company had cash of approximately
$1,761 and an accumulated deficit of approximately $21 million. The Company has incurred recurring losses, experienced recurring negative
operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional
working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue
operations. Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for
the twelve months from the date of these financial statements.

  22  

Contractual
Obligations

As
of March 31, 2025 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Off-Balance
Sheet Arrangements

We